- Home
- GUTS vs AGEN Comparison
GUTS vs AGEN Comparison
Compare GUTS & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GUTS
- AGEN
- Stock Information
- Founded
- GUTS 2010
- AGEN 1994
- Country
- GUTS United States
- AGEN United States
- Employees
- GUTS N/A
- AGEN N/A
- Industry
- GUTS
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GUTS
- AGEN Health Care
- Exchange
- GUTS NYSE
- AGEN Nasdaq
- Market Cap
- GUTS 110.1M
- AGEN 96.2M
- IPO Year
- GUTS 2024
- AGEN 2000
- Fundamental
- Price
- GUTS $1.80
- AGEN $3.48
- Analyst Decision
- GUTS Buy
- AGEN Buy
- Analyst Count
- GUTS 2
- AGEN 3
- Target Price
- GUTS $18.00
- AGEN $10.50
- AVG Volume (30 Days)
- GUTS 382.2K
- AGEN 419.4K
- Earning Date
- GUTS 02-02-2025
- AGEN 03-13-2025
- Dividend Yield
- GUTS N/A
- AGEN N/A
- EPS Growth
- GUTS N/A
- AGEN N/A
- EPS
- GUTS N/A
- AGEN N/A
- Revenue
- GUTS $97,000.00
- AGEN $160,427,000.00
- Revenue This Year
- GUTS N/A
- AGEN N/A
- Revenue Next Year
- GUTS N/A
- AGEN $36.13
- P/E Ratio
- GUTS N/A
- AGEN N/A
- Revenue Growth
- GUTS N/A
- AGEN 59.00
- 52 Week Low
- GUTS $1.74
- AGEN $2.50
- 52 Week High
- GUTS $14.50
- AGEN $19.69
- Technical
- Relative Strength Index (RSI)
- GUTS 40.50
- AGEN 58.60
- Support Level
- GUTS $1.91
- AGEN $3.08
- Resistance Level
- GUTS $2.10
- AGEN $3.29
- Average True Range (ATR)
- GUTS 0.16
- AGEN 0.26
- MACD
- GUTS -0.01
- AGEN 0.05
- Stochastic Oscillator
- GUTS 6.12
- AGEN 80.36
About GUTS FRACTYL HEALTH INC
Fractyl Health Inc is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including type 2 diabetes and obesity. The company focuses on transforming metabolic disease treatment from chronic symptomatic management to durable disease modifying therapies that target the organ level root causes of T2D and obesity.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).